Despite sliding past an interim futility analysis in February 2015, Anthera Pharmaceuticals Inc.'s blisibimod couldn't hit the phase III endpoint against systemic lupus erythematosus (SLE) in the trial called CHABLIS-SC1 – an "obviously disappointing" outcome that the firm's chief medical officer (CMO), William Shanahan, blamed on the high placebo response.